Get Live Data

SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Sandoz Group Ag Share Price
  4. Sandoz Group Ag Share Regulatory News

Pin to quick picksSandoz Group Ag Regulatory News (0SAN)

Sandoz Group Ag Information

Share Price Information for Sandoz Group Ag (0SAN)

Share Price is delayed by 15 minutes
Get Live Data
67.02    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap:
0SAN Live PriceLast checked at - London Stock Exchange

Intraday Sandoz Group Ag Share Chart

  • This share is an international stock.
Date   Source Headline
12th Aug 20256:00 amGNWSandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
7th Aug 20256:00 amGNWSandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
30th Jul 20256:15 amGNWSandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
1st Jul 20251:56 pmGNWSandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
2nd Jun 20256:00 amGNWSandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
21st May 20254:30 pmGNWSandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
30th Apr 20256:00 amGNWSandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
29th Apr 20254:00 pmGNWSandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
15th Apr 202512:50 pmGNWShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
14th Apr 20253:00 pmGNW[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
14th Apr 20256:00 amGNWSandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
31st Mar 20254:39 pmGNWSandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
5th Mar 20255:59 amGNWSandoz reports strong FY 2024 results and Q4 2024 sales
24th Feb 20256:00 amGNWSandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
3rd Feb 20256:00 amGNWFrancisco Ballester to retire; Peter Stenico appointed President Region International
14th Jan 20256:00 amGNWSandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
17th Dec 20246:00 amGNWSandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
15th Nov 20246:00 amGNWSandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
30th Oct 20246:00 amGNWSandoz reports third-quarter and nine-month 2024 sales
12th Aug 20246:00 amGNWSandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
8th Aug 20246:00 amGNWSandoz reports second-quarter sales and half-year 2024 results
25th Jul 20246:00 amGNWSandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
1st Jul 20246:00 amGNWFDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
22nd May 20246:00 amGNWSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
30th Apr 202411:25 amGNWShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
30th Apr 20246:00 amGNWSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
22nd Apr 20246:00 amGNWSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
21st Mar 20241:00 pmGNWSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
13th Mar 20246:00 amGNWSandoz reports fourth quarter 2023 sales and full-year 2023 results
5th Mar 20246:24 pmGNWSandoz receives FDA approval for first and only denosumab biosimilars
5th Mar 20246:00 amGNWSandoz announces nominations to the Board of Directors and leadership change
4th Mar 20246:00 amGNWSandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
29th Feb 20246:00 amGNWSandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
1st Feb 20246:15 amGNWSandoz announces changes in the Board of Directors
31st Jan 20246:00 amGNWSandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
22nd Jan 20246:00 amGNWSandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
21st Nov 20236:00 amGNWSandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
10th Nov 20231:02 pmGNWSandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
8th Nov 20235:46 pmGNWSandoz successfully issues EUR 2.0 billion inaugural Eurobonds
26th Oct 20234:45 pmGNWSandoz successfully issues CHF 750 million in inaugural bonds
24th Oct 20236:15 amGNWSandoz reports year-to-date sales for the first nine months of 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
19TL
Stand.chart. 43
LSE
0.00%
KF99
Citi Fun 26
LSE
0.00%
0QO2
Burkhalter Hold
LSE
0.00%
KF86
Citi Fun 28
LSE
0.00%
0RHT
Sif Holding Ord
LSE
0.00%
Trending
QHE
Quantum Helium
LSE
20.00%
FORG
Forgent
LSE
2.35%
GGP
Greatland Resources
LSE
12.12%
ALRT
Defence Holdings
LSE
1.31%
EZJ
easyJet
LSE
0.00%